TherapeuticsMD (TXMD) PT Raised to $12 at Oppenheimer Following FDA Approval
Tweet Send to a Friend
Oppenheimer raised its price target on TherapeuticsMD (NASDAQ: TXMD) to $12.00 (from $10.00) while maintaining a Outperform rating.Analyst Jay Olson ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
